372 related articles for article (PubMed ID: 35175630)
1. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
Ringheim GE; Wampole M; Oberoi K
Front Immunol; 2021; 12():662223. PubMed ID: 34803999
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).
Owens TD; Brameld KA; Verner EJ; Ton T; Li X; Zhu J; Masjedizadeh MR; Bradshaw JM; Hill RJ; Tam D; Bisconte A; Kim EO; Francesco M; Xing Y; Shu J; Karr D; LaStant J; Finkle D; Loewenstein N; Haberstock-Debic H; Taylor MJ; Nunn P; Langrish CL; Goldstein DM
J Med Chem; 2022 Apr; 65(7):5300-5316. PubMed ID: 35302767
[TBL] [Abstract][Full Text] [Related]
4. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria.
Bernstein JA; Maurer M; Saini SS
J Allergy Clin Immunol; 2024 May; 153(5):1229-1240. PubMed ID: 38141832
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.
Langrish CL; Bradshaw JM; Francesco MR; Owens TD; Xing Y; Shu J; LaStant J; Bisconte A; Outerbridge C; White SD; Hill RJ; Brameld KA; Goldstein DM; Nunn PA
J Immunol; 2021 Apr; 206(7):1454-1468. PubMed ID: 33674445
[TBL] [Abstract][Full Text] [Related]
6. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
7. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
8. A Fast and Clean BTK Inhibitor.
Gabizon R; London N
J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
[TBL] [Abstract][Full Text] [Related]
9. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
10. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Good L; Benner B; Carson WE
Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
[TBL] [Abstract][Full Text] [Related]
12. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
13. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
14. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
15. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Liu J; Chen C; Wang D; Zhang J; Zhang T
Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
[TBL] [Abstract][Full Text] [Related]
16. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
Rip J; Van Der Ploeg EK; Hendriks RW; Corneth OBJ
Crit Rev Immunol; 2018; 38(1):17-62. PubMed ID: 29717662
[TBL] [Abstract][Full Text] [Related]
17. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
[TBL] [Abstract][Full Text] [Related]
18. BTK Inhibitors in Haematology: Beyond B Cell Malignancies.
Leitinger DE; Kaplan DZ
Transfus Med Rev; 2022 Oct; 36(4):239-245. PubMed ID: 36376164
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase is a possible therapeutic target in microscopic polyangiitis.
Nakade I; Tamura Y; Hashimoto F; Ariza Y; Hotta S; Fujigaya H; Arai S; Taniguchi M; Ogawa H; Nishibata Y; Masuda S; Nakazawa D; Tomaru U; Ishizu A
Arthritis Res Ther; 2023 Nov; 25(1):215. PubMed ID: 37932784
[TBL] [Abstract][Full Text] [Related]
20. Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.
Patsatsi A; Murrell DF
Front Med (Lausanne); 2021; 8():708071. PubMed ID: 34447768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]